Project Grant R37CA302948
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $653K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $659,201 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on the integrated stress response in glioblastoma pathogenesis and response to therapy. The funded research investigates how glioma stem cells survive and proliferate within the hostile glioblastoma microenvironment through adaptive stress response mechanisms. The work focuses on the...
- The National Institutes of Health National Cancer Institute awarded the University of California, Los Angeles $404,972 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to decode mechanisms behind durable immunotherapy responses in glioblastoma. The research uses spatial transcriptomics, high-plex immunofluorescence, and single-cell sequencing to map immune architecture in tumor samples from long-term survivors treated with autologous tumor lysate-pulsed dendritic cell...
- The National Cancer Institute awarded Duke University $509,581 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, to conduct research on innate immune memory for glioma immunotherapy. The research investigates how to enhance the antitumor efficacy of PVSRIPO, a live-attenuated recombinant poliovirus, in patients with recurrent glioblastoma. Clinical trials showed that intratumoral PVSRIPO infusion achieved long-term survival in approximately 20 percent of recurrent...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $675,617 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate intercellular metabolic and signaling mechanisms of brain cancer-glia communication driving glioblastoma progression. The project examines how glioblastoma cells reprogram brain microglia—the brain's resident immune cells—to create an immunosuppressive tumor microenvironment that promotes tumor growth. The research focuses on an...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Institutes of Health National Cancer Institute awarded The Washington University $645,185 under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, to develop and test a combination immunotherapy approach for glioblastoma. The recipient will conduct research on an "expand and pull" strategy combining long-acting interleukin-7 (IL-7) with oncolytic virus therapy to expand peripheral CD8+ T cells and recruit them into the glioblastoma tumor microenvironment....
- The National Cancer Institute awarded The Ohio State University $567,754 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on immunotherapy for glioblastoma by targeting an immunoregulatory neuropeptide. The research addresses glioblastoma (GBM), the most lethal primary brain tumor, which exhibits remarkable resistance to immunotherapy due to CD8 T cell exclusion and dysfunction driven by immunosuppressive myeloid cells, particularly tumor-associated...
- The National Cancer Institute awarded Northwestern University $496,357 under the Cancer Treatment Research program (CFDA 93.395) on April 17, 2026, to investigate mechanisms of immunosuppression in glioblastoma and develop therapeutic interventions targeting tumor-associated macrophage polarization. The research centers on the peri-necrotic niche within IDH-wildtype glioblastoma tumors, where hypoxic glioma cells and immunosuppressive tumor-associated macrophages aggregate in spatial...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell-intrinsic immunogenicity in glioblastoma. The research program will expose glioblastoma neurosphere models to 3,792 small...